HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Summary Full Text Full Text (PDF) All Versions of this Article: fj.06-6511fjev1 20/14/2609    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Turmelle, Y. P. Articles by Rudnick, D. A. Search for Related Content PubMed PubMed Citation Articles by Turmelle, Y. P. Articles by Rudnick, D. A.

Rosiglitazone inhibits mouse liver regeneration

Yumirle P. Turmelle^*, Olga Shikapwashya^*, Shu Tu^*, Paul W. Hruz^*,, Qingyun Yan^* and David A. Rudnick^*,,1

^* Department of Pediatrics,

Department of Molecular Biology and Pharmacology, and

Department of Cellular Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA

¹Correspondence: Department of Pediatrics, Washington University School of Medicine, 660 S. Euclid Ave., Box 8208, St. Louis, MO 63110, USA. E-mail: rudnick_d{at}kids.wustl.edu

ABSTRACT

The remarkable regenerative potential of the liver is well known. Recent investigations have shown that this regenerative response is impaired in mouse models of fatty liver disease. Other studies demonstrate that mice engineered for liver-specific overexpression of the peroxisome proliferator activated receptor gamma (PPAR) develop significant hepatic steatosis. These observations suggest that precise regulation of hepatic PPAR activity may be essential for normal liver regeneration. To test this hypothesis, we analyzed the effects of PPAR-activating thiazolidinediones on liver regeneration in the rodent partial hepatectomy model. Thiazolidinediones with different PPAR-activating potencies were administered to mice, and those mice were subjected to partial hepatectomy and analyzed for resulting effects on hepatocellular proliferation and signaling pathways important during normal liver regeneration. The results showed that thiazolidinediones suppress liver regeneration with efficacies that correlate with their relative PPAR-activating potencies. These studies provide the first evidence linking regulation of PPAR activity and the hepatic regenerative response.—Turmelle, Y. P., Shikapwashya, O., Tu, S., Hruz, P. W., Yan, Q., Rudnick, D. A. Rosiglitazone inhibits mouse liver regeneration.